Following HMA treatment, an increase in BCL‐2 and a decrease in MCL‐1 levels have been described; venetoclax treatment may reduce the apoptotic threshold in MDS and allow response to HMAs even in cells previously resistant to HMA treatment.12 Here, BCL2 is linked to myelodysplastic syndrome.